PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Ritonavir

Drugs in development · updated 30 October 2026

Ritonavir: clinical trials and development status

Other names and codes: Norvir

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 25 August 1996

As of 30 October 2026 Ritonavir is in 12 active clinical trials (recruiting or ongoing, phases I–III) for 28 diseases. The most advanced phase is III.

12Active trials
IIIMost advanced phase
28Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Ritonavir and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
COVID-19III4NCT05852873
HIV infectionIII2NCT07792096
Community-acquired pneumoniaIII1NCT02735707
InfluenzaIII1NCT02735707
Lung diseaseIII1NCT02735707
PneumoniaIII1NCT02735707
Respiratory diseaseIII1NCT02735707
Respiratory tract infectionIII1NCT02735707
Non-small-cell lung carcinomaI–II2NCT05914116
Bile duct neoplasmI–II1NCT05150691
Biliary tract neoplasmI–II1NCT05150691
Breast neoplasmI–II1NCT05150691
CarcinomaI–II1NCT05150691
CholangiocarcinomaI–II1NCT05150691
Endometrial neoplasmI–II1NCT05150691
Esophageal squamous cell carcinomaI–II1NCT05914116
Gastrointestinal neoplasmI–II1NCT05150691
Head and neck squamous cell carcinomaI–II1NCT05914116
Hepatocellular carcinomaI–II1NCT05914116
Liver neoplasmI–II1NCT05150691
Lung small cell carcinomaI–II1NCT05914116
MelanomaI–II1NCT05914116
MetastasisI–II1NCT05150691
NeoplasmI–II1NCT05150691
Prostatic NeoplasmsI–II1NCT05914116
Stomach neoplasmI–II1NCT05150691
Uterine cervix neoplasmI–II1NCT05914116
GliomaI1NCT06428045

Everything on Ritonavir

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch